Etanercept biosimilar (Sandoz)

依那西普生物类似药 （Sandoz）

Report date: 2025/07/01 11:11:44

Base Information

Drug NameEtanercept biosimilar (Sandoz)
Drug Alias NameEtanercept-szzsErelziGP-2015
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion proteinBiologics > Biosimilar
Mechanisms of ActionTumor necrosis factor β inhibitorsTumor necrosis factor α inhibitors
TargetsTumor necrosis factor βTumor necrosis factor α
Therapy Area/IndicationsPlaque psoriasisPsoriasisArthritis, Rheumatoid +[6] 
Global Approved IndicationsPlaque psoriasisPsoriasisArthritis, Rheumatoid +[6] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2016/08/30
Country/TerritoryCzechiaBulgariaUnited States +[17] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesClariant Produkte (Schweiz) Ag
China Registration ClassN/A

Develop Information

Active CompaniesSandozSandoz Gmbh
Inactive CompaniesN/A
Active IndicationsPlaque psoriasisPsoriasisArthritis, Rheumatoid +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeL04AB01
Related LinksWikipediaDrugBankKEGG